|
|
|
|
|||||
|
|
|
Fresenius Medical Care AG & Co. FMS reported first-quarter 2025 adjusted earnings per share (EPS) of 44 cents, which surpassed the Zacks Consensus Estimate by 2.1%. The bottom line improved 22.2% year over year. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Revenues of $5.14 billion (EUR 4,881 million) missed the Zacks Consensus Estimate by 2.2%. The company’s reported revenues increased 3.3% year over year and 1.2% at constant currency (cc). Also, revenues were up 5.4% organically.
Per management, during the first quarter, divestitures realized as part of the portfolio optimization plan affected revenue development by -260 basis points.
Shares of this company gained nearly 3.6% in today’s pre-market trading. The company’s shares have gained 21.1% year to date against the industry’s decline of 10.7%. The S&P 500 Index has decreased 5% in the same period.
Fresenius Medical implemented a new operating model in 2024 and started reporting under two new segments, Care Delivery and Care Enablement.
Care Delivery
The segment’s revenues were up 1.8% on a year-over-year basis but down 0.9% at cc. However, revenues gained 4.2% on an organic basis.
Revenues in the U.S. markets improved 6.4% reportedly and gained 4.1% on an organic basis. The top line improved 3.2% year over year at cc. Per management,a growing value-based care business, reimbursement rate increases, and a favorable payor mix, as well as exchange rate effects, had a positive impact on the segment’s growth, compensating for a decrease in dialysis days.
Per management, during the first quarter of 2025, U.S. same-market treatment growth was flat year over year.
International sales declined 19.1% reportedly and 19% at cc but gained 4.8% on an organic basis. The decline was due to divestments realized as part of the portfolio optimization plan and a decrease in dialysis days, which was partially offset by organic growth. The organic growth was supported by accelerated same-market treatment growth of 2.5%.
Care Enablement
The segment’s revenues increased 5.4% year over year reportedly and 4.9% at cc as well as organically. The growth was driven by volume growth in all the company’s geographical regions and continued positive pricing momentum. Per management, volume-based procurement in China developed in line with expectations, supporting volume growth while acting as a headwind to price development.
In the quarter under review, Fresenius Medical’s gross profit improved 0.9% year over year. However, the gross margin contracted 60 basis points (bps) to 24.3%.
Selling, general & administrative expenses declined 3.2% on a reported basis. Research and development expenses decreased 9% year over year.
Adjusted operating income improved 11.4% from the prior-year quarter. The adjusted operating margin in the first quarter expanded 58 bps to 8%.
Fresenius Medical Care AG & Co. KGaA price-consensus-eps-surprise-chart | Fresenius Medical Care AG & Co. KGaA Quote
In 2025, Fresenius Medical expects revenue growth to be positive, with a low-single-digit percent rate compared to the prior year. The company also expects operating income to grow by a high-teens to high-twenties percent rate compared to the prior year.
FMS exited the first quarter on a mixed note, with its earnings and revenues surpassing and missing their respective consensus estimate. Overall pricing momentum also supported growth in the Care Enablement segment. However, the effects of elevated mortality will likely continue to have a negative impact on sales.
Per management, during the first quarter, the FME25 transformation program continued its positive momentum, delivering EUR 68 million additional sustainable savings while related one-time costs, treated as special items, amounted to EUR 28 million. The company confirmed its full-year target of around EUR 180 million in additional annual savings, totaling EUR 750 million by 2025-end.
The company’s continued divestment of its non-core and dilutive assets appears promising, as it will help focus on its core and growing categories, while also boosting its cash resources.
FMS carries a Zacks Rank #2 (Buy) at present.
Some other top-ranked stocks from the industry that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX.
CVS Health, carrying a Zacks Rank of 2, reported first-quarter 2025 adjusted EPS of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CVS Health has a long-term estimated growth rate of 11.4%. CVS’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 13.3%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| 3 hours | |
| 3 hours | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite